Gilead Sciences, Inc.

NASDAQ: GILD
Share price (4/24/24): $67.08
Market cap (4/24/24): $83.5 billion

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

13 Gilead Sciences, Inc. Expert Interviews, now on BamSEC.

Powered by Tegus.

Financials Filter

ended 12/31/23 FY 2023

ended 09/30/23 Q3

ended 06/30/23 Q2

ended 03/31/23 Q1

ended 12/31/22 FY 2022

Prospectuses and Registrations Filter

Third party tender offer – amended

Third party tender offer – amended

Third party tender offer – amended

Third party tender offer – amended

Third party tender offer – amended

Ownership Filter

Leap Therapeutics Inc

Leap Therapeutics Inc

Xilio Therapeutics Inc

Xilio Therapeutics Inc

Xilio Therapeutics Inc

News Filter

Announces Completion of Acquisition of Cymabay

Change in Directors, Officers or Compensation

-- Gilead Adds Seladelpar to Portfolio, a PPARδ Agonist for the Treatment of Primary Biliary Cholangitis (PBC) With FDA Priority Review and Anticipated U.S. Approval in Third Quarter of 2024

Announces Fourth Quarter and Full Year 2023 Financial Results

Ted Love, MD, Joins Gilead Sciences’ Board of Directors

Proxies Filter

Additional info about upcoming vote

Definitive proxy

Preliminary proxy

Letter to shareholders

Other Filter

Scanned paper annual report submission

Correspondence with the SEC

Letter from the SEC

Correspondence with the SEC

Letter from the SEC